|
| Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA(R) for the Treatment of Irritable Bowel Syndrome with ... |
29 Apr 08, 23:09 |
|
| Sucampo Pharmaceuticals, Inc., (NASDAQ: SCMP, Sucampo Pharmaceuticals) and Takeda Pharmaceutical Company Limited (TSE: 4502, Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Sucampo Pharmaceuticals' supplemental New Drug Application (sNDA) for AMITIZA(R) (lubiprostone) 8 mcg capsules ... |
| more |
|
